Sector News

Chinese buyer resurrects US Boehringer plant

November 3, 2014
Life sciences
Chinese company UniTao has agreed to buy a Boehringer Ingelheim manufacturing site in Petersburg, US, which was scheduled to be closed by the end of the year with the loss of 240 jobs.
 
UniTao will use the active pharmaceutical ingredient (API) manufacturing facility site to make APIs for global distribution, and intends to employ up to 376 people. The company has indicated that the availability of a skilled workforce was a favourable factor in its decision to buy the site.
 
By Phillip Broadwith
 

Related News

September 18, 2020

Eli Lilly, Amgen join forces to scale production of COVID-19 antibody cocktails

Life sciences

Months of fervid research have whittled away most potential options to treat patients with COVID-19, a group of antibody cocktails still hold promise. Eli Lilly believes so strongly in its contender that it’s […]

September 16, 2020

Takeda unveils new Boston R&D manufacturing center for cell therapy pipeline push

Life sciences

Japanese drugmaker Takeda has trumpeted its plan in recent years to cut billions of dollars in costs and pivot around oncology and rare diseases. A key part of that strategy […]

September 15, 2020

AstraZeneca, Oxford restart stalled COVID-19 test as Pfizer ramps up trial numbers for its vaccine

Life sciences

Just under a week after it stopped its key phase 3 pandemic vaccine test, AstraZeneca and the University of Oxford have been given the green light to restart in the […]